Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Cardiology
•
Endocrinology
•
Preventive Cardiology
•
Lipid Disorders
How does the TACTiC trial's success with a web app for statin self-management influence your stance on nonprescription statins for primary prevention amidst statin underuse?
TACTiC trial
Related Questions
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
When and for whom should we consider adding bempedoic acid to the lipid lowering regimen?
When would you consider initiating patients with CAD and aortic stenosis on PCSK9 inhibitors (as an adjunct to statin therapy), given favorable findings in the FOURIER trial?
Have you begun to incorporate high dose IV iron infusions into your practice for patients newly started on hemodialysis with TSAT < 30% and ferritin < 400 to reduce risk for non-fatal CV events based on findings from the PIVOTAL trial?
For patients with hypertension who have normal filling pressures following right cardiac catheterization, can hypertension still be attributed to volume overload?
If prompted as an outpatient, how do you counsel patients on the rare cardiac complications of vaccinations including myocarditis?
What is your approach to counseling a patient with stable but severe multivessel coronary disease if the patient does not wish to undergo bypass surgery?
What are your top takeaways from ACC 2024?
How do you factor in a positive family history of premature CAD into ASCVD risk estimation?
When would you consider initiation of bempedoic acid for statin intolerant patients (i.e. LDL threshold, comorbidities)?
